Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Binqi Ye

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Pharmaceutical Statistics|November 23, 2022
Sample size re-estimation in Phase 2 dose-finding: Conditional power versus Bayesian predictive powerQingyang Liu, Guanyu Hu, Binqi Ye, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 25, 2020
Early Combination Therapy with Linagliptin and Metformin in People with Type 2 Diabetes Improves Glycemic Control to HbA1c ≤ 6.5% without Increasing Hypoglycemia: Pooled Analysis of Two Randomized Clinical TrialsQian Lv, Jie Shen, Lin Miao, et al.
Diabetes, Obesity & Metabolism|October 19, 2020
Efficacy and safety of linagliptin as add-on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trialWenying Yang, Xiangjin Xu, Tao Lei, et al.
Dermatology and Therapy|September 21, 2023
Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding StudyA David Burden, Robert Bissonnette, Alexander A Navarini, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Pharmaceutical Statistics|November 23, 2022
Sample size re-estimation in Phase 2 dose-finding: Conditional power versus Bayesian predictive powerQingyang Liu, Guanyu Hu, Binqi Ye, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|April 25, 2020
Early Combination Therapy with Linagliptin and Metformin in People with Type 2 Diabetes Improves Glycemic Control to HbA1c ≤ 6.5% without Increasing Hypoglycemia: Pooled Analysis of Two Randomized Clinical TrialsQian Lv, Jie Shen, Lin Miao, et al.
Diabetes, Obesity & Metabolism|October 19, 2020
Efficacy and safety of linagliptin as add-on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trialWenying Yang, Xiangjin Xu, Tao Lei, et al.
Dermatology and Therapy|September 21, 2023
Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding StudyA David Burden, Robert Bissonnette, Alexander A Navarini, et al.
Pageof 1